Elvucitabine

ATC code

• none

CAS Number

• 181785-84-2 ^Y

PubChem CID

• 469717

ChemSpider

• 412628

Elvucitabine

Clinical data
ATC code	none
Identifiers
IUPAC name 4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
CAS Number	181785-84-2 Y
PubChem CID	469717
ChemSpider	412628
UNII	M09BUF90C0
ChEMBL	ChEMBL38700 N
NIAID ChemDB	060327
CompTox Dashboard (EPA)	DTXSID20171185
Chemical and physical data
Formula	C9H10FN3O3
Molar mass	227.195 g·mol−1
3D model (JSmol)	Interactive image
SMILES c1c(c(nc(=O)n1[C@@H]2C=C[C@@H](O2)CO)N)F
InChI InChI=1S/C9H10FN3O3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14H,4H2,(H2,11,12,15)/t5-,7+/m1/s1 Key:HSBKFSPNDWWPSL-VDTYLAMSSA-N
NY (what is this?)  (verify)

Elvucitabine is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Achillion Pharmaceuticals, Inc. for the treatment of HIV infection.^[1]

Elvucitabine belongs to a class of HIV drugs called nucleoside reverse transcriptase inhibitors (NRTIs).^[2] By blocking reverse transcriptase enzymes, NRTIs prevent HIV from multiplying and can reduce the amount of HIV in the body.

Elvucitabine is similar in chemical structure to the FDA-approved NRTIs lamivudine (brand name Epivir) and emtricitabine (brand name Emtriva). However, in vitro studies have suggested that elvucitabine may affect certain HIV strains resistant to other NRTIs, such as lamivudine and emtricitabine.

Studies have also suggested that elvucitabine may be effective against hepatitis B virus (HBV).^[3] Mechanism of action of Elvucitabine ; reveals that it acts by inhibiting reverse transcriptase which interferes with generation of DNA copies of viral RNA.^[4]

Currently, it is in Phase II clinical trials.^[5]